SEC-sourced researchBeta
SNDX
Syndax Pharmaceuticals Inc
Company comparison ↗
Data passport
- CIK
- 0001395937
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Feb 26, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 0.0000 | Feb 26, 2026 |
| December 2024 | 23,680,000.0000 | Feb 26, 2026 |
| December 2025 | 172,352,000.0000 | Feb 26, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 172,352,000.0000 | -285,422,000.0000 | -322,980,000.0000 | 529,706,000.0000 | 465,076,000.0000 | Feb 26, 2026 |
| December 2024 | 23,680,000.0000 | -318,758,000.0000 | -274,903,000.0000 | 724,816,000.0000 | 436,692,000.0000 | Feb 26, 2026 |
| December 2023 | 0.0000 | -209,360,000.0000 | -160,601,000.0000 | — | — | Feb 26, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $172.35M | December 2025 | Feb 26, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $23.68M | December 2024 | Feb 26, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$285.42M | December 2025 | Feb 26, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$322.98M | December 2025 | Feb 26, 2026 | 10-K |
| Total assetsAssets | $529.71M | December 2025 | Feb 26, 2026 | 10-K |
| Total liabilitiesLiabilities | $465.08M | December 2025 | Feb 26, 2026 | 10-K |